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ABSTRACT
Objectives: To assess whether automated screening in the 
cytologic examination of Papanicolaou smear slides results 
in smaller margins of error than manual screening.
Methods: We compared cytotechnologists’ performance and 
reproducibility of manual and automated screening of 10,165 
consecutive cervical cytology slides examined at Barretos 
Cancer Hospital using the FocalPoint system.
Results: In total, 83% of atypical squamous cells of 
undetermined significance and greater were classified as 
quintiles 1 and 2; no high-grade squamous intraepithelial 
lesions and greater were observed in quintile 5. No 
statistically significant differences were found between 
manual and automated screening, using cervical biopsy 
specimens as the gold standard.
Conclusions: FocalPoint safely screened high-grade lesions, 
which can be valuable for high-workload routines.
The World Health Organization estimates that more 
than 69.05 million Brazilian women older than 15 years are 
at risk of developing cervical cancer.1 In Brazil, prevention 
is accomplished through a Papanicolaou (Pap) smear follow-
ing routine cytologic screening established by the Ministry 
of Health of Brazil in 1988.2,3 For several reasons, estimates 
of cancer incidence and mortality have remained virtually 
unchanged in the past decades in Brazil.
The manual screening of Pap smear slides by a cytotech-
nologist is a monotonous activity, leading to fatigue, which 
can result in morphologic changes, misinterpretation, and 
false-negative results. The number of slides examined daily 
must be low (40-50 per day) to avoid errors. Cytotechnolo-
gists differ in productivity, screening time, and accuracy in 
interpreting the results of the slides, which can vary by day 
of the week and even (morning or afternoon) time of day.4 
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To try to reduce false-negative results, new technologies for 
the preparation and screening of slides of cervical cytology 
specimens are currently available. Liquid-based cytology 
(LBC) was designed to reduce the overlapping of cells and 
facilitate the detection of abnormalities in automated screen-
ing.5 In the well-known SurePath (TriPath Imaging, Burling-
ton, NC) method, preparation of cells 13 mm in diameter is 
obtained without undesirable losses of material and cellular 
crowding.5 This type of cell preparation maintains a high 
standard of quality, while automated screening is believed to 
improve a process fraught with cognitive difficulties.
One of the most used automated screening systems 
worldwide is the BD FocalPoint GS Imaging System (FPGS) 
(BD, Burlington, NC), which can evaluate both LBC and 
conventional preparations.6 The use of these devices is pre-
sumed to serve as a primary screening tool with important 
improvements in internal quality control, which ensures 
cytologic examination routines with smaller margins of error.
Taking into account the potential usefulness of com-
puter-assisted evaluation of LBC preparations routinely 
examined at Barretos Cancer Hospital, we sought to evalu-
ate FocalPoint performance to identify and classify cervical 
injuries safely and critically analyze the introduction of the 
robot as an internal quality control device.
Materials and Methods
The cytologic samples were collected from May 2010 
through August 2011 from the following sources: women 
referred to the Barretos Cancer Hospital who had a previ-
ous suspicious examination elsewhere, women examined 
in mobile units of the Preventing Cancer Hospital of Bar-
retos, and women who had gynecologic consultations in the 
municipalities that send their tests to the sector of pathol-
ogy at Barretos Cancer Hospital. The mean (SD) age was 
45 (13.9) years (range, 13-96 years). We analyzed 10,165 
cervical cytology cases prepared by the SurePath liquid-
based method.
Study Design
The screening of the slides and statistical analyses were 
independently performed by professionals from the Barretos 
Cancer Hospital. In the first round, the cytotechnologists 
evaluated 10,165 slides prepared in the liquid-based Sure-
Path method with a light microscope under routine condi-
tions. Then, all slides were analyzed by the FocalPoint sys-
tem, which classified the cellular changes into quintiles as 
previously reported.6,7 Briefly, this classification was made 
in accordance with the probability of abnormality of each 
slide. There are 5 quintiles, with quintile 1 having the high-
est probability of abnormality and 5 having the least.6,7 We 
introduced quintile 99 to identify those cases that were clas-
sified as quintile 5 but had no image available for review, 
as well as those cases classified as Process Review, which 
means that the cellular alterations found by the computer 
were not able to be classified within the morphologic param-
eters recorded in the system and needed to be reviewed 
manually by the cytotechnologist/cytopathologist.
After about a year of manual screening, the same 
group of cytotechnologists conducted microscope-auto-
mated screening in the Guided Station of the FocalPoint 
system. The cases with cytologic changes in the manual and 
automated arms (atypical squamous cells of undetermined 
significance and greater [ASC-US+]) were reviewed by a 
group of 6 cytopathologists, keeping the same proportion of 
cases from the first round for each cytopathologist in both 
arms. Analyses of sensitivity and specificity were performed 
exclusively for patients who underwent biopsy of the cervix.
Ethics
Participants gave informed consent to participate in the 
study, which was approved by the ethics committee of Bar-
retos Cancer Hospital (No. 244/2009).
Conflict of Interest
BD Brazil (São Paulo) supported part of the study with 
the SurePath collection kits and equipment. The study design, 
the screening of the slides, and statistical analyses were 
performed independently by professionals from the Barretos 
Cancer Hospital.
Results
Of the total 10,165 slides, 9,847 (96.9%) qualified for 
revision, and 318 (3.1%) cases were not classified by Focal-
Point (manual revision was suggested by the computer—
quintile 99).
The classification into quintiles of cases read by cyto-
technologists in the automated arm was analyzed, and the 
results are listed in ❚Table 1❚. Most cases scored ASCUS+ 
by cytotechnologists were classified as quintile 1; 90% and 
33% of high-grade squamous intraepithelial lesions (HSIL) 
and adeno/squamous cell carcinoma were classified as 
quintiles 1 and 2, respectively; and the rest of the cases of 
adeno/squamous cell carcinoma were selected for screening 
of the entire slide. Cases of invasive carcinomas that were 
not selected in quintiles 1 and 2 were classified as quintile 
5 without opening images (in our routine, we renamed this 
quintile 99). Generally, quintile 99 represented cases in 
which cellular changes were so numerous and so pleomor-
phic that FocalPoint provided an alert that the slides should 
be fully reviewed by the observer.
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The sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) were calculated 
from patients who had a biopsy of the cervix. ❚Table 2❚ 
shows the results for cytotechnologist screening alone and 
the completed process involving cytotechnologists’ screen-
ing and cytopathologists’ final result.
Discussion
We evaluated FocalPoint’s performance in classifying 
into quintiles LBC slides that were read by cytotechnolo-
gists. Most of the high-grade lesions, as well as ASCUS+ 
alterations, were classified as quintile 1 or 2, which endorses 
the usefulness of FocalPoint for screening and for quality 
control tools. HSIL and carcinomas not classified as quintile 
1 or 2 were allocated to quintile 99. All these results clearly 
show that FocalPoint has an excellent discriminatory power 
to classify cases with cytologic abnormalities.
FocalPoint ranked in quintiles all slides within standard 
screening (review: slides into which FocalPoint separates the 
images to be read in Guided Stations). This classification is 
applied according to the probability of abnormal cells pres-
ent in each slide analyzed. Quintile 1 represents the highest 
probability of abnormality, with quintiles 4 and 5 represent-
ing the least likely.
The results of this study correlated, in part, with the 
data of other studies. In a study conducted by Parker et al,7 
90% of HSIL and 83% of HSIL+ (HSIL, adenocarcinoma in 
situ [AIS], and carcinoma) were classified as quintiles 1 and 
2. Wilbur et al8 evaluated 12,313 slides and found that 700 
of 1,275 ASCUS+ were classified as quintile 1, as well as 
94.6% of HSIL+ (HSIL, AIS, and carcinoma) in the first 2 
quintiles. These data are important to ratify the discriminatory 
power and reliability of FocalPoint that can be expected under 
routine conditions.
To evaluate the sensitivity, specificity, PPV, and NPV 
of automated and manual screening, we used the biopsy 
result as the gold standard. No statistical significance was 
found between the 2 screening methods, using criteria for 
cervical intraepithelial neoplasia grade 2 or more (CIN2+) 
biopsy specimens as a cutoff for both arms, with and without 
cytopathologist revision. Even without a significant differ-
ence, however, the sensitivity was approximately 50% and 
specificity was approximately 80%, numbers that reflect the 
performance of Pap cytology testing under standard condi-
tions.9 The cytotechnologists who participated in the study 
are experienced in detecting abnormalities in gynecologic 
cytology, which may explain the similarity of the results 
of the 2 screening techniques and without cytopathologist 
interference. Moreover, it is known that a good screening 
method for cervical cancer should be efficient to detect those 
who really have a cervical intraepithelial lesion because a 
false-positive result can cause anxiety for the patient and 
more government spending on additional tests to detect 
❚Table 1❚
FocalPoint Classification According to the Quintiles Distribution
 FocalPoint Cytologic Diagnoses, No. (%)
Quintile Negative, No. (%) ASCUS ASC-H LSIL HSIL Adeno/CEC AGC Total, No. (%)
1 1,516 (16.3) 59 (55.7) 74 (64.9) 115 (72.8) 101 (84.2) 0 6 (46.2) 1,871 (19.0)
2 1,809 (19.4) 24 (22.6) 16 (14.0) 23 (14.6) 7 (5.8) 1 (33.3) 2 (15.4) 1,882 (19.1)
3 1,891 (20.3) 9 (8.5) 10 (8.8) 11 (7.0) 3 (2.5) 0 1 (7.7) 1,925 (19.6)
4 1,889 (20.2) 6 (5.7) 6 (5.3) 4 (2.5) 2 (1.7) 0 2 (15.4) 1,909 (19.4)
5 1,814 (19.4) 1 (0.9) 5 (4.4) 2 (1.3) 0 0 0 1,822 (18.5)
99a 410 (4.4) 7 (6.6) 3 (2.6) 3 (1.9) 7 (5.8) 2 (66.7) 2 (15.4) 434 (4.4)
Total 9,329 (100) 106 (100) 114 (100) 158 (100) 120 (100) 3 (100) 13 (100) 9,843 (100)
Adeno/CEC, adenocarcinoma/cell squamous carcinoma; AGC, atypical glandular cell; ASC-H, atypical squamous cells of undetermined significance not excluding high-grade 
lesion; ASCUS, atypical squamous cells of undetermined significance; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.
a Quintile 5 without opening images; in our routine we renamed this quintile 99.
❚Table 2❚
Accuracy of Manual and Automated Cytology Reading 
to Predict CIN2+ (Biopsy) Using HSIL+ as the Cytologic 
Criteriona
 Manual Computer- 
Characteristic Screening Assisted Screening
Without cytopathologist review n = 337 n = 337
   Sensitivity 52.8 (44.8-60.7) 45.3 (37.5-53.4)
   Specificity 81.8 (75.3-87.2) 85.8 (79.8-90.6)
   Positive predictive value 72.7 (63.6-80.5) 74.5 (64.7-82.8)
   Negative predictive value 65.5  (58.8-71.7) 63.2 (56.2-69.3)
   AUC (ROC curve) (*1b) 0.67 (0.62-0.72) 0.66  (0.60-0.71)
With cytopathologist review n = 337 n = 334
   Sensitivity 59.6 (51.6-67.3) 60.4 (52.3-68.0)
   Specificity 83.0 (76.6-88.2) 76.0 (69.0-82.1)
   Positive predictive value 76.2 (67.8-83.3) 69.6 (61.2-77.1)
   Negative predictive value 69.2 (62.5-75.4) 67.9 (60.8-74.3)
   AUC (ROC curve) (*2c) 0.71 (0.66-0.76) 0.68 (0.63-0.73)
AUC, area under curve; CIN2+, cervical intraepithelial neoplasia grade 2 and more; 
HSIL+, high-grade squamous intraepithelial lesion and greater; ROC, receiver 
operating characteristic.
a Values are presented as % (95% confidence interval) unless otherwise indicated. 
Cytologic cutoff: HSIL+; biopsy: CIN2+.
b Comparison of manual and computer-assisted screening AUCs: P = .47.
c Comparison of manual and computer-assisted screening: AUCs: P = .21.
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cervical cancer, whereas a false-negative result generates a 
false sense of security that can lead to neglecting events that 
are critical for the woman’s life.10 The PPV is preferred to 
evaluate the screening test efficiency, and in this study, the 
PPV results were notable: the PPV performance ranged from 
72.7% to 74.5% for cytotechnologists and from 76.2% to 
69.9% for cytopathologists in manual and automated screen-
ing, respectively, using HSIL+ cytologic criteria.
The sensitivity and specificity of a technique can be 
calculated in several ways without always using biopsy as 
the gold standard. In a UK study examining 73,266 SurePath 
and ThinPrep slides (Hologic-Cytyc, Marlborough, MA) 
that compared manual screening with automated screening 
with the ThinPrep Imaging System and FPGS, the authors 
concluded that automated screening was 8% less sensitive 
than manual screening for CIN2+.11 Our results, however, 
are in agreement with a study in Finland, a country with 
an active national program tracking rare cases of cervical 
cancer. Anttila et al12 also found no statistically signifi-
cant differences between manual and automated screening. 
Another study in 2 large laboratories in Ontario, Canada, had 
similarities with the current study. Colgan and colleagues13 
compared the performance of FPGS and manual screening 
in 10,233 cases and found no differences in detecting low-
grade squamous intraepithelial lesions and greater (LSIL+) 
(including HSIL and invasive carcinomas), but they found 
higher false-negative rates for LSIL and ASC-US in FPGS 
than with manual screening.
Cengel et al14 compared SurePath slides in manual and 
automated screening and concluded that the sensitivity of 
the automated method was better when it was used as the 
gold standard for manual screening (96%) rather than using 
biopsy of the cervix (93%). This unique way of evaluating 
the performance of a method can be subject to criticism. 
However, considering that manual tracing has been used for 
decades in millions of annual tests, the premise of the work 
has provided a new vision of how to evaluate the introduc-
tion of a new method. In 1 study that implemented FPGS 
in Connecticut, slides in a SurePath liquid base read in the 
16 months preceding implementation of FPGS were used as 
the gold standard, resulting in an increase in the detection of 
ASCUS and LSIL with automated screening.15 In 302 cases 
prepared in liquid-based ThinPrep, high levels of satisfac-
tory samples for screening were demonstrated, even after 
patients had received radiation therapy, with a PPV of 25% 
for LSIL and 100% for carcinoma.16
The advent of human papillomavirus (HPV) vaccination 
is likely to decrease precancerous lesions due to decreased 
severe injuries. In this scenario, the low NPVs and PPVs 
of conventional cytology will be even lower, which further 
complicates the recognition by cytotechnologists of cellular 
changes that require new logistics and new features, such as 
automated screening combined with the HPV test, to act with 
the efficiency expected.17
Recently, Sweeney and Wilbur18 evaluated the Focal-
Point utility for cytotechnologist productivity. Because it 
is very difficult to recruit and train new cytotechnologists 
and because the vaccine era will decrease the (already) low 
sensitivity of cytology (it is presumed that high-grade abnor-
malities will diminish), FPGS could help improve workload 
without a decline in the quality of results. The authors found 
that productivity after implementation of FPGS increased 
gradually with a period of implementation.15
To the best of our knowledge, this is the first study in 
South America that demonstrates the utility of FocalPoint 
in cytologic screening. Even without major differences 
between automated and manual screening, the use of Focal-
Point in the daily routine of a cytology laboratory is valu-
able and also helps to avoid possible false results in routine 
screening, especially in centers where the cytotechnologists’ 
workload is high (80-100 slides per day). Resources assessed 
are also suitable for internal quality control, overcoming the 
current system proposed by Brazilian health authorities that 
requires the revision of all ASCUS+, unsatisfactory smears, 
and 10% of negative cases. Although important, this system 
of quality control leaves aside the causes that give rise to 
false-negative results, passing off this serious problem by 
checking only 10% of patient samples selected within a 
given period.
The use of FocalPoint has shown that it can prevent 
HSIL+ false-negative cases from being released, with the 
possibility to be correct in real time and thereby reducing 
diagnostic distortions. Identifying errors and their causes 
offers the possibility of a continuous education process 
where internal control is just one more element in the role of 
quality assurance in cytology.
Address reprint requests to Dr Longatto-Filho: Laboratory of 
Medical Investigation (LIM) 14, Faculty of Medicine, University 
of São Paulo, 1246-903 São Paulo, Brazil; e-mail: longatto16@
hotmail.com.
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